[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.
Laurie Keating, insider at Alnylam Pharmaceuticals
Laurie Keating Insider Alerts

Get notified the next time Laurie Keating buys or sells Alnylam Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Laurie Keating Insider Information

Laurie Bartlett Keating joined Alnylam in 2014 with more than 25 years of executive experience at high-growth technology and biotechnology companies.

Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high-growth technology companies, including Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team. Based on her leadership at Sybase, Laurie was named one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Laurie practiced law at McCutchen, Doyle, Brown and Enersen (which became Bingham McCutchen and is now a part of Morgan, Lewis & Bockius) in San Francisco.

She has a Doctor of Jurisprudence degree from the University of California, Hastings College of the Law, and a BA in Economics from the University of California at Berkeley. Laurie is a member of the Board of Directors of Immuneering Corporation and MassBIO, a former member of the Board of Hydra Biosciences, and a past chair of the BIO General Counsels Committee.

What is Laurie Keating's net worth?

The estimated net worth of Laurie Keating is at least $1.80 million as of August 5th, 2021. Ms. Keating owns 13,008 shares of Alnylam Pharmaceuticals stock worth more than $1,799,136 as of January 20th. This net worth approximation does not reflect any other investments that Ms. Keating may own. Learn More.

What is Laurie Keating's salary?

As the EVP of Alnylam Pharmaceuticals, Inc., Ms. Keating earned a total compensation package of $2,434,148.00 in 2020. Ms. Keating earned a salary of $544,600.00, options awards of $1,598,986.00, non-equity compensation of $265,000.00, and other compensation of $25,562.00.

How do I contact Laurie Keating?

The corporate mailing address for Ms. Keating and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]

Has Laurie Keating been buying or selling shares of Alnylam Pharmaceuticals?

Laurie Keating has not been actively trading shares of Alnylam Pharmaceuticals in the last ninety days. Most recently, Laurie Keating sold 10,000 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $188.95, for a transaction totalling $1,889,500.00. Following the completion of the sale, the executive vice president now directly owns 13,008 shares of the company's stock, valued at $2,457,861.60.

Who are Alnylam Pharmaceuticals' active insiders?

Alnylam Pharmaceuticals' insider roster includes Jeffrey Dunn (CEO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), and Akshay Vaishnaw (Insider).

Are insiders buying or selling shares of Alnylam Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 241,044 shares worth more than $36,396,167.13. The most recent insider tranaction occured on December, 23rd when insider Akshay Vaishnaw sold 2,879 shares worth more than $549,687.47. Insiders at Alnylam Pharmaceuticals own 2.3 % of the company.

Information on this page was last updated on 12/23/2021.

Laurie Keating Insider Trading History at Alnylam Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2021Sell10,000$188.95$1,889,500.0013,008View SEC Filing Icon  
7/12/2021Sell6,812$178.96$1,219,075.526,944View SEC Filing Icon  
6/9/2021Sell1,734$154.00$267,036.005,132View SEC Filing Icon  
1/12/2021Sell14,941$160.20$2,393,548.202,234View SEC Filing Icon  
7/13/2020Sell47,250$160.67$7,591,657.5016,433View SEC Filing Icon  
4/20/2020Sell10,000$139.00$1,390,000.0024,492View SEC Filing Icon  
1/29/2020Sell6,337$119.00$754,103.0014,932View SEC Filing Icon  
1/27/2020Sell41,037$117.70$4,830,054.9024,632View SEC Filing Icon  
6/20/2018Sell1,563$105.04$164,177.5216,063View SEC Filing Icon  
3/20/2018Sell1,562$149.83$234,034.4616,062View SEC Filing Icon  
3/13/2018Sell20,000$145.00$2,900,000.0024,500View SEC Filing Icon  
12/20/2017Sell6,249$121.20$757,378.8017,749View SEC Filing Icon  
12/1/2017Sell30,000$135.89$4,076,700.0041,500View SEC Filing Icon  
5/30/2017Buy11,500$65.35$751,525.0011,500View SEC Filing Icon  
See Full Table

Laurie Keating Buying and Selling Activity at Alnylam Pharmaceuticals

This chart shows Laurie Keating's buying and selling at Alnylam Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $138.31
Low: $137.90
High: $146.44

50 Day Range

MA: $172.53
Low: $138.31
High: $199.59

2 Week Range

Now: $138.31
Low: $125.08
High: $212.00


576,250 shs

Average Volume

727,465 shs

Market Capitalization

$16.54 billion

P/E Ratio


Dividend Yield



Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!